Dr. Martens targets £3.7bn valuation in stock market float
Dr. Martens hopes it will fetch a valuation of just under £4bn when it lists on the Stock Exchange in London for the first time next week.
The heritage footwear brand has announced it will set a 370p-per-share offer price when it floats next Wednesday, 3 February.
That will imply a valuation of £3.7bn for the company, which is making 35% of the business available to investors.
CEO Kenny Wilson said: “We have been delighted by the strong levels of interest, engagement and support from such a high quality selection of institutional investors.
“The successful transformation of Dr. Martens is a great story, and what is even more exciting is the huge potential ahead.
“We are proud to take our place as a London listed company, both delivering as a successful plc and, more importantly, continuing to grow our brand around the world.”
The business is currently owned by private equity firm Permira, which plans to retain a stake after the float.
Dr. Martens boots are already sold in more than 60 countries, and customers buy around 11m pairs every year. However the brand sees room for further expansion.
Announcing the growth plans a few weeks ago, Wilson said the brand has “significant global growth potential”, and eyed the further investment that a stock market listing could bring.
However, Wilson and his fellow executives will not be able to cash in straight away. Dr. Martens management, directors, employees and some former executives will not be allowed to sell their shares for at least a year, while other owners will be locked in for 180 days.
However, on the day, Permira will sell 350m shares, netting it around £1.3bn if it manages to hit the 370p share price.